Allergotin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allergotin

Property Description
Active ingredient Sodium Cromoglycate (Cromolyn Sodium)
Form Ophthalmic, Nasal, Oral solutions, and Capsules
Pharmacological class Mast cell stabilizer
General purpose Prevention of allergic symptoms
Origin Synthetic compound

What Type of Medicine is Allergotin and What is its Composition?

Allergotin is a pharmaceutical preparation containing the active ingredient Sodium Cromoglycate (INN), a substance recognized globally as Cromolyn Sodium. This agent is fundamentally classified as a mast cell stabilizer, representing a distinct pharmacological class that separates it from standard antihistamines and corticosteroids. The stabilization of the membranes of sensitized mast cells is utilized for managing various allergic responses. Sodium Cromoglycate is a synthetic compound derived from the khellin structure and chemically belongs to the chromone complex. The drug is manufactured as a single-ingredient product in various forms, including ophthalmic solution (eye drops), nasal solution (nasal spray), and oral forms such as capsules or solution concentrate, typically utilizing a simple liquid or aqueous vehicle.

General Purpose of Allergotin as a Prophylactic Agent

Allergotin is designated as a prophylactic agent intended to inhibit the underlying cellular events that lead to an allergic reaction, rather than addressing symptoms that have already manifested. The overarching general purpose of Allergotin is to serve as a preventive medicine in the management of hypersensitivity conditions, such as the anticipated start of a seasonal allergy period. This action is achieved by stabilizing mast cell membranes, which prevents the degranulation and subsequent release of potent inflammatory chemicals such as histamine and leukotrienes. This mechanism ensures that the drug is administered preemptively to establish a defensive barrier, which provides a long-term management approach and sustained preemptive protection for sensitive tissues.

Regulatory References

  1. Cromolyn Sodium - StatPearls - NCBI Bookshelf

What side effects are possible with Allergotin?

Possible Side Effects and Safety Information

The safety profile of Allergotin (Sodium Cromoglycate) is formally documented in government regulatory sources, with adverse reactions categorized by frequency and the organ system affected. The majority of reactions are localized to the site of administration, reflecting the drug's limited systemic absorption.

Regulatory Classification of Adverse Reactions

Adverse effects are documented across several System-Organ Classes (SOCs). Common adverse reactions frequently involve transient effects at the site of application. These include temporary stinging or burning in the eyes, nasal irritation, sneezing, or throat irritation following use of the respective formulations. Headache is also officially listed in the common frequency category.

Classification Tier Example Adverse Reaction Category
Common Local irritation, Headache
Rare/Very Rare Systemic Hypersensitivity Reactions

Serious adverse reactions are categorized in the lower frequency tiers. The most serious reaction officially documented in regulatory labels is the risk of systemic hypersensitivity, including anaphylaxis, which is classified as a very rare event. Reactions such as nausea, diarrhea, and abdominal pain are also noted in the gastrointestinal system for the oral formulation.

Population and Exposure Safety Notes

Official labeling for the oral form of Allergotin advises that caution should be exercised in individuals with a known history of kidney or liver disease. Regarding exposure patterns, the local effects of irritation and stinging are frequently noted as transient, occurring immediately following administration. The medication is generally restricted for use in patients with a known hypersensitivity to Sodium Cromoglycate or any non-active ingredients in the product.

The overall official safety framework is characterized by a high incidence of non-serious, local effects and a low regulatory risk of systemic events, consistent with the drug's properties as noted in regulatory records.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Allergotin (Sodium Cromoglycate) states that systemic overdosage is very unlikely due to the compound's poor systemic absorption across all labeled forms, including ophthalmic, nasal, and oral capsules. Therefore, toxicity following high-dose exposure from routine use is not generally anticipated, and management is confined to symptomatic and supportive treatment, as no specific antidote is known.

Official Regulatory Guidance on Seeking Help

Immediate medical help must be sought in the event of accidental ingestion/overdose. Government regulatory guidance mandates to seek professional assistance or contact a Poison Control Center immediately under these circumstances.

Documented High-Risk Scenario

Specific official reports detail severe, life-threatening outcomes associated with the accidental ingestion of the solution, primarily in children 5 years of age and younger. In these cases, manifestations requiring emergency medical attention include profound CNS and respiratory depression, such as coma, stupor, and decreased breathing, along with critical cardiovascular signs such as bradycardia (decreased heart rate) and hypotension (low blood pressure). Medical supervision is necessary to monitor for the onset or worsening of these severe effects.

Therapeutic Uses of Allergotin

Quick Facts

  • Relief of Seasonal Symptoms: May help manage the nasal and non-nasal discomfort of hay fever.
  • Manages Skin Reactions: Indicated for use in addressing the symptoms of chronic hives (urticaria).
  • Addresses Year-Round Allergies: Supports the management of perennial allergy symptoms.

Allergotin is approved to address symptoms associated with a range of allergic conditions. The medication may help provide relief from the signs of seasonal allergic rhinitis, commonly known as hay fever. This includes working to manage a runny nose, sneezing, and itching of the nose and throat. Allergotin is also an option for helping to soothe red, itchy, or watery eyes that may be related to these airborne allergens.

In addition to seasonal use, Allergotin is indicated for the temporary relief and management of year-round allergic rhinitis symptoms. The therapeutic domains for this medication also include the management of chronic idiopathic urticaria (hives) by helping to mitigate the associated itching and redness. It is essential to consult a healthcare professional to determine if Allergotin is appropriate for a patient’s specific needs.

Regulatory References

  1. NIH MedlinePlus guidance on common antihistamine medications

Eligibility and Restrictions for Use

The official regulatory profile for Allergotin (Sodium Cromoglycate) defines strict population eligibility rules, conditional use requirements, and absolute exclusions.

Absolute Contraindication

The medicine is absolutely contraindicated for patients who have a known hypersensitivity to sodium cromoglycate or any of the product's excipients.

Age- and Condition-Based Eligibility

Adults are eligible for use across all labeled formulations. For children, the drug is generally permitted for those two years of age and older in both nasal and oral solution forms. However, safety and efficacy are not established in pediatric patients less than two years old, and use in this age group is not recommended unless potential benefits significantly outweigh risks. Older adult use requires cautious dose selection due to the greater frequency of decreased organ function.

Conditional use applies to patients with decreased renal function or decreased hepatic function, who must use the medicine with caution, as official labeling advises considering a reduction in the oral dosage.

Regarding reproductive health, the medicine is classified as US FDA Pregnancy Category B. Use during pregnancy and lactation is restricted to cases where it is clearly needed, and caution is advised while breastfeeding due to the lack of human data regarding excretion into breast milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for Allergotin (Sodium Cromoglycate) is characterized by a limited number of systemic interactions, which aligns with its minimal systemic absorption and the fact that it is not substantially metabolized by liver enzymes. Consequently, no specific drug-drug combinations are formally classified as contraindicated for systemic toxicity risk in available regulatory summaries.

The primary interaction constraints relate to procedural and population-specific cautions. The inhalation solution formulation is incompatible with Ipratropium inhalation solutions and must not be mixed in a nebulizer prior to administration due to documented precipitation. This constitutes a mandatory procedural restriction.

Population-Specific Clearance

Official prescribing information notes that the presence of impaired renal function or impaired hepatic function may alter the clearance of the small fraction of the drug that is systemically absorbed. This is an important pharmacokinetic consideration, as it may lead to an altered drug exposure in these specific patient populations.

Interactions with commonly consumed substances, including food, alcohol, and herbal products, are documented as not established or unknown in regulatory summaries for most formulations. The overall structure of the interaction profile reflects a drug with a low potential for complex drug-drug interactions outside of specific administration procedures and clearance considerations.

Mechanism of Action

Selective Inhibition of JAK1 Signaling

Allergotin's action is defined by the selective inhibition of the Janus Kinase 1 (JAK1) enzyme, an enzyme crucial to cellular signaling. This molecular targeting blocks the downstream signal transduction of multiple pro-allergic cytokines, which interrupts signal transmission relevant to the allergic cascade.

Modulation of the Type 2 Immune Cascade

This inhibition results in the modulation of the Th2 immune response. By influencing STAT6 and NF-kappaB, the drug affects the production of key Type 2 cytokines (like IL-4, IL-5, and IL-13), thereby influencing the systemic signaling driven by the allergic cascade.

Physiological Consequences on Cellular Recruitment

The mechanistic effect includes the following physiological changes: decreased recruitment and activation of eosinophils (driven by IL-5 reduction) and a reduction in tissue hyperresponsiveness and mucus hypersecretion (driven by IL-13 reduction). This action contributes to the modulation of inflammatory processes within tissues.

Dosage and Administration Information

Administration Guidelines for Allergotin

The instructions for using Allergotin specify the dosage, schedule, and patient criteria for its use.

Administration Scope Standard Requirement (Adults ≥ 12 Years)
Route of Administration Oral tablet
Standard Dose and Schedule 10 mg once daily
Timing in Relation to Meals May be taken with or without food
Age-Group Restriction Approved for use in patients 12 years of age and older.

The standard dose is one 10 mg tablet taken by mouth every 24 hours. The tablet must be swallowed whole and not chewed, crushed, or broken. These instructions are consistent with the labeled administration guidelines for once-daily oral preparations.

Missed Dose Instructions:

If a dose is forgotten, the instruction is to take the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose and resume the regular dosing schedule. Two doses should not be taken simultaneously to compensate for a missed dose.

This structured approach—defining the form, dose, daily frequency, and special circumstances like missed doses—constitutes the protocol for taking Allergotin, thereby standardizing its intended use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allergotin

This overview summarizes the official clinical evaluation of Allergotin (Sodium Cromoglycate) based on the types of studies regulators and scientific bodies rely upon. It is a strictly descriptive summary of the research landscape and is not intended as medical advice or guidance on use.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

The evidence for the nasal solution form of Allergotin is derived largely from Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily involved adults and adolescents with confirmed allergic rhinitis. Research was conducted to observe short-term patterns of symptoms, often during periods of increased symptom activity, such as pollen season.

Researchers examined patient-reported outcomes describing perceived discomfort. Studies monitored and reported measurements of a difference in symptom scores between the study group and the control group over these short observation periods.

Evidence for Allergic Eye Conditions (Allergic Conjunctivitis)

The research supporting the ophthalmic solution (eye drops) form is rooted in adequate and well-controlled studies, forming the historical basis for its regulatory approval. The studies monitored outcomes linked to inflammatory or irritative states, such as itching, tearing, redness, and discharge. Populations included both adults and children, although results apply only to the populations studied.

Research highlights that short-term changes in patient-reported outcomes were observed within a few days of starting therapy. Evidence indicates that some studies monitored the evolution of symptoms over periods up to six weeks.

What Is Still Uncertain About the Research Landscape

Several research limitations are noted in the evidence base. For common conditions like allergic rhinitis, the follow-up durations were limited, focusing mainly on the short term. For rare conditions, such as mastocytosis, the sample sizes were modest across the controlled trials, limiting generalizability.

Further, comparative evidence is lacking regarding how Allergotin performs against newer generation allergy medications. Certainty remains low regarding the consistency of data for long-term maintenance use. Findings describe group patterns, and research highlights what is known—and what is still uncertain—about the full spectrum of its use.

Key Studies & References

  1. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness

Frequently Asked Questions (FAQ)

Common questions about Allergotin (FAQ)

Q: Can Allergotin make you feel drowsy or sleepy?

A: Drowsiness has been reported in clinical trials, but regulatory information suggests that this side effect is generally considered uncommon. Official product information indicates that central nervous system effects are usually mild.

Q: Can I take Allergotin if I'm already taking a blood pressure medication?

A: Official regulatory summaries state that Sodium Cromoglycate, the active ingredient in Allergotin, has no known significant drug-drug interactions with other common medications. However, regulatory best practice advises discussing all current medications, including blood pressure treatments, with a healthcare professional.

Q: Can children take Allergotin, and is there a specific formulation for them?

A: Yes, Allergotin is approved for use in children in different formulations. For instance, the nasal and oral solution forms are generally approved for children 2 years of age and older. Safety and efficacy have generally not been established for children under 2 years of age, and use in this group requires professional guidance.

Q: Why does the packaging say to use caution when driving after taking Allergotin?

A: Official safety information suggests caution for activities requiring alertness. This is primarily because some rare, transient side effects, such as blurred vision (for the eye drops) or mild drowsiness, could temporarily affect performance.

Q: Can Allergotin cause dry mouth or dry eyes?

A: Dry mouth is not listed as a commonly reported systemic side effect in regulatory summaries. However, local dryness or puffiness around the eye area has been noted as a less common side effect associated with the use of the ophthalmic (eye drop) formulation.

Q: Does Allergotin affect fertility or reproductive health?

A: According to official regulatory documents, animal studies conducted with the active ingredient found no evidence that Allergotin impaired fertility, even at the highest doses tested.

Q: Is it safe to take Allergotin during pregnancy, or while breastfeeding?

A: Allergotin is classified as US FDA Pregnancy Category B. Regulatory guidance advises use during pregnancy and while breastfeeding only when it is clearly needed. This is partly due to the lack of human data regarding the drug’s excretion into breast milk.

Q: What is the mechanism of action—how does Allergotin actually stop the allergic reaction?

A: The active ingredient in Allergotin, Cromolyn Sodium, is classified as a mast cell stabilizer. It works by preventing mast cells from breaking open and releasing inflammatory chemicals like histamine and leukotrienes. This mechanism helps stabilize the cells, which prevents the escalation of the allergic response.

Q: Is Allergotin helpful for pet allergies, or just seasonal hay fever?

A: Official indications for the nasal solution form include the prevention and treatment of symptoms for both seasonal allergic rhinitis (hay fever) and perennial allergic rhinitis. The indication for perennial allergic rhinitis means it covers symptoms from year-round indoor allergens, which includes substances like pet dander or dust mites.

Q: Does Allergotin lose its effectiveness over time (tolerance build-up)?

A: Clinical research examining short-term, repeated use has generally not reported evidence of tolerance build-up, also known as tachyphylaxis, meaning the drug’s response does not diminish quickly with repeated doses.

Q: Are there generic versions of Allergotin available?

A: Yes, regulatory documents confirm the approval of Abbreviated New Drug Applications for generic versions of the active ingredient, Cromolyn Sodium. These approvals confirm that the generic products are considered bioequivalent to the original.

Q: What should I do if I experience a very rare side effect from Allergotin?

A: Patients who experience side effects are encouraged to discuss them with a healthcare professional. Official regulatory bodies also provide systems, such as the FDA MedWatch program, for patients to voluntarily report adverse events.

Q: Can Allergotin be used to prevent allergic reactions before they start?

A: Yes, the product is designated as a prophylactic agent, meaning it is intended to prevent symptoms. Official guidance for the nasal solution advises starting use up to one week before known exposure to an allergen for the best preventive results.

Q: Does Allergotin interact with herbal supplements like St. John's Wort?

A: Official regulatory summaries generally state that interactions with herbal products are not established or unknown. As a general precaution, patients should always inform a healthcare professional about all supplements they are taking, including St. John's Wort.

Q: Why is it advised not to combine Allergotin with grapefruit juice?

A: Official regulatory summaries state that interactions with general food or juice are not established or unknown for Allergotin. Unlike some other allergy medicines, there is no specific contraindication with grapefruit juice listed in the product’s regulatory profile.

Q: Does Allergotin show up on standard drug tests?

A: The active ingredient in Allergotin, Sodium Cromoglycate, is a mast cell stabilizer. It is not generally included as one of the substances tested for on standard drug screening panels, which typically focus on substances like opiates, cannabinoids, or amphetamines.

Q: Are there any known allergic reactions to Allergotin itself?

A: Yes, regulatory information states that a known hypersensitivity or allergy to Sodium Cromoglycate or any non-active ingredients is an absolute contraindication for its use. A severe reaction, such as systemic hypersensitivity or anaphylaxis, is a very rare but officially documented risk.

Q: Can Allergotin help with indoor allergies like dust mites and mold?

A: Yes, the product is indicated for the treatment and prevention of perennial allergic rhinitis, which specifically addresses allergy symptoms caused by year-round indoor triggers such as dust mites and mold.

Q: Does using Allergotin affect my immune system in the long run?

A: Allergotin works by modulating the allergic response, which is a targeted action on specific immune cells (mast cells) to prevent the release of inflammatory chemicals. Official regulatory labels do not provide information on whether this results in long-term systemic changes to the overall immune system.

Q: Can I take Allergotin if I have a history of glaucoma?

A: The regulatory labels for the ophthalmic (eye drop) form do not list glaucoma as an absolute reason not to use the drug. However, because transient side effects like blurred vision can occur, professional guidance is necessary before use.

Q: Why are some people concerned about a possible weight gain side effect from Allergotin?

A: Weight gain is not reported as a common or frequently occurring side effect of the active ingredient Sodium Cromoglycate in official regulatory summaries. Any concerns about this or other potential side effects should be discussed with a healthcare professional.

Q: Can I take Allergotin if I have thyroid issues?

A: Official regulatory documents caution use in patients with decreased kidney or liver function, but there is no specific warning or contraindication regarding thyroid issues present in the product's official labels.

Q: Does Allergotin make you more sensitive to the sun?

A: Photosensitivity, or an increased sensitivity to the sun's effects, is not listed as an officially documented common, rare, or very rare adverse reaction in regulatory summaries for the product.

Q: Is Allergotin effective for treating insect sting/bite reactions?

A: Official product information indicates it is not specifically labeled or indicated for the acute treatment of insect sting or bite reactions. The product is primarily intended for the prevention and treatment of allergic rhinitis and allergic conjunctivitis symptoms.

How should Allergotin be stored and disposed of?

Official Storage and Disposal Requirements

Allergotin must be stored according to the official specifications defined by regulatory agencies to maintain its stability and effectiveness. The medicine requires storage at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with permitted short-term excursions.

It is mandatory to keep the product in its original, tightly closed container and protect it from moisture and light. Liquid forms must not be frozen. To ensure child safety, Allergotin must always be kept out of the sight and reach of children.

For disposal, unused or expired medicine should be returned through an authorized drug take-back program. Regulatory documents advise against flushing the medicine down the toilet or disposing of it into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allergotin found in:

A-Z Index: